Concord Biotech has made an equity investment of $1,500 in Stellon Biotech Inc, USA. This investment represents the subscription of 15 million equity shares at a price of $0.0001 per share resulting into 75% ownership in Stellon Biotech Inc.
This investment has been made with the objective to expand business operations in USA for the company, through its own subsidiary with a local partner in the United States of America (USA). The company proposed to utilize this U.S. subsidiary to distribute and sell its products in USA.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
